Literature DB >> 23612438

Genotype-phenotype study in type V osteogenesis imperfecta.

Meena Balasubramanian1, Michael J Parker, Ann Dalton, Cecilia Giunta, Uschi Lindert, Luiz C Peres, Bart E Wagner, Paul Arundel, Amaka Offiah, Nicholas J Bishop.   

Abstract

Type V osteogenesis imperfecta (OI) presents with moderate-to-severe skeletal deformity and is characterized by hyperplastic callus formation at fracture sites and calcification of the interosseous membranes of the forearm and lower leg. The facial dysmorphism is not well characterized and has not been described in previous reports. Inheritance is autosomal dominant, although the genetic aetiology remained unknown until very recently. The aims of this study were to establish the genetic aetiology in patients with type V OI and further characterize patients with this condition, and to ascertain whether they have a similar clinical phenotype and facial dysmorphism. Three families (one mother-daughter pair and two singletons) were identified with the above features and further investigations (molecular genetic analysis and skin biopsy including electron microscopy, histology and collagen species analysis) were performed. Accurate phenotyping of patients with type V OI was performed. PCR amplification was performed using the Sheffield Diagnostic Genetics Service pyrosequencing assay for the interferon-induced transmembrane protein-5 (IFITM5) gene. All the patients had been confirmed to have a heterozygous variant, c.[-14C>T];[=], in the 5'-UTR of the IFITM5 gene, which is located in the transcribed region of this gene. This recurrent mutation, in IFITM5, also known as bone-restricted interferon-induced transmembrane protein-like protein or BRIL, encodes a protein with a function in bone formation and plays an important role in osteoblast formation. All four patients in this study appear to have similar clinical features and facial dysmorphism, including a short, up-turned nose, a small mouth, a prominent chin and greyish-blue sclerae. Skin biopsy in one patient showed clumping of elastic fibres and normal biochemical analysis of collagen. We have been able to characterize patients with type V OI further and confirm the genetic aetiology in this distinct form of OI. Accurate phenotyping (including describing the common facial features) before investigations is important to enable the useful interpretation of genetic results and/or target-specific gene testing.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23612438     DOI: 10.1097/MCD.0b013e32836032f0

Source DB:  PubMed          Journal:  Clin Dysmorphol        ISSN: 0962-8827            Impact factor:   0.816


  15 in total

Review 1.  IFITM5 mutations and osteogenesis imperfecta.

Authors:  Nobutaka Hanagata
Journal:  J Bone Miner Metab       Date:  2015-06-02       Impact factor: 2.626

2.  PHENOTYPIC VARIABILITY IN INDIVIDUALS WITH TYPE V OSTEOGENESIS IMPERFECTA WITH IDENTICAL IFITM5 MUTATIONS.

Authors:  Jamie Fitzgerald; Paul Holden; Hollis Wright; Beth Wilmot; Abigail Hata; Robert D Steiner; Don Basel
Journal:  J Rare Disord       Date:  2013-12

3.  Type V OI primary osteoblasts display increased mineralization despite decreased COL1A1 expression.

Authors:  Adi Reich; Alison S Bae; Aileen M Barnes; Wayne A Cabral; Aleksander Hinek; Jennifer Stimec; Suvimol C Hill; David Chitayat; Joan C Marini
Journal:  J Clin Endocrinol Metab       Date:  2014-11-11       Impact factor: 5.958

4.  Hypermineralization and High Osteocyte Lacunar Density in Osteogenesis Imperfecta Type V Bone Indicate Exuberant Primary Bone Formation.

Authors:  Stéphane Blouin; Nadja Fratzl-Zelman; Francis H Glorieux; Paul Roschger; Klaus Klaushofer; Joan C Marini; Frank Rauch
Journal:  J Bone Miner Res       Date:  2017-06-26       Impact factor: 6.741

5.  Clinical and Molecular Characterization of Osteogenesis Imperfecta Type V.

Authors:  Evelise Brizola; Eduardo P Mattos; Jessica Ferrari; Patricia O A Freire; Raquel Germer; Juan C Llerena; Têmis M Félix
Journal:  Mol Syndromol       Date:  2015-09-03

Review 6.  Osteogenesis imperfecta.

Authors:  Antonella Forlino; Joan C Marini
Journal:  Lancet       Date:  2015-11-03       Impact factor: 79.321

7.  Ocular characteristics and complications in patients with osteogenesis imperfecta: a systematic review.

Authors:  Sanne Treurniet; Pia Burger; Ebba A E Ghyczy; Frank D Verbraak; Katie R Curro-Tafili; Dimitra Micha; Nathalie Bravenboer; Stuart H Ralston; Ralph de Vries; Annette C Moll; Elisabeth Marelise W Eekhoff
Journal:  Acta Ophthalmol       Date:  2021-05-19       Impact factor: 3.988

8.  The IFITM5 mutation c.-14C > T results in an elongated transcript expressed in human bone; and causes varying phenotypic severity of osteogenesis imperfecta type V.

Authors:  Syndia Lazarus; Aideen M McInerney-Leo; Fiona A McKenzie; Gareth Baynam; Stephanie Broley; Barbra V Cavan; Craig F Munns; Johannes Egbertus Hans Pruijs; David Sillence; Paulien A Terhal; Karena Pryce; Matthew A Brown; Andreas Zankl; Gethin Thomas; Emma L Duncan
Journal:  BMC Musculoskelet Disord       Date:  2014-03-27       Impact factor: 2.362

Review 9.  IFITMs restrict the replication of multiple pathogenic viruses.

Authors:  Jill M Perreira; Christopher R Chin; Eric M Feeley; Abraham L Brass
Journal:  J Mol Biol       Date:  2013-09-25       Impact factor: 5.469

10.  Childhood Osteoporosis and Presentation of Two Cases with Osteogenesis Imperfecta Type V.

Authors:  Nina Bratanic; Bojana Dzodan; Katarina Trebusak Podkrajsek; Sara Bertok; Barbara Ostanek; Janja Marc; Tadej Battelino; Magdalena Avbelj Stefanija
Journal:  Zdr Varst       Date:  2015-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.